Irinotecan News and Research

RSS

Irinotecan hydrochloride is approved by the Food and Drug Administration (FDA) to be used with other drugs to treat colorectal cancer that has metastasized (spread to other parts of the body). It is also approved to treat metastatic colorectal cancer that has recurred (come back) or gotten worse after earlier chemotherapy. In addition to the uses that have been approved by the FDA, irinotecan hydrochloride is sometimes used to treat other types of cancer. Irinotecan hydrochloride is also being studied in the treatment of other types of cancer.

Epigenetic manipulation may improve breast cancer treatment responses

Researchers explore the possibility of increasing TROP2 ADC activity by enhancing the expression of TROP2 on cancer cells.

15 Aug 2023

Experts develop commercial formulation Campto for colorectal cancer

Announcing a new publication for Acta Materia Medica journal. The compound 7-ethyl-10-hydroxy-camptothecin (SN38) is a broad-spectrum antitumor agent whose applications are greatly limited by its poor solubility. Therefore, irinotecan, the hydrophilic derived prodrug of SN38, has been developed as the commercial formulation Campto® for colorectal cancer.

25 Feb 2023

Chemotherapy in the afternoon proved to be effective for female lymphoma patients

Chemotherapy is a commonly used regimen for cancer treatment, but it is also a double-edged sword. While the drugs are highly effective at killing cancer cells, they are also notorious for killing healthy cells in the body.

27 Jan 2023

Chemotherapy schedule affects treatment outcomes in female DLBCL patients

24 Jan 2023

Four-drug chemotherapy regimen provides longer overall survival for metastatic pancreatic ductal adenocarcinoma

A four-drug chemotherapy regimen provided longer overall survival than a two-drug combination in a Phase 3 clinical trial for metastatic pancreatic ductal adenocarcinoma.

20 Jan 2023

Research identifies unique vulnerabilities in ALT cancers that can serve as novel therapeutic targets

In a study recently published in Cancer Research, a journal of the American Association for Cancer Research, a team of researchers led by C. Patrick Reynolds, M.D., Ph.D., director for the Texas Tech University Health Sciences Center School of Medicine Cancer Center, sought to expand upon his lab's previous research that showed ALT tumors identified by a biomarker known as C-circles share a common biology that confers vulnerabilities to be exploited for cancer therapy.

10 Aug 2022

Biochemist finds new way to protect healthy leukocytes during chemotherapy

A biochemist from RUDN and IBMC has found a way to protect healthy leukocytes during leukemia chemotherapy. Small nitrogen-containing polyamine molecules give the necessary protection.

14 Jul 2022

TTUHSC researcher secures $1.9 million grant to investigate vulnerabilities in ALT cancers

The National Cancer Institute, part of the National Institutes of Health, recently awarded a five-year, $ $1.9 million grant to C. Patrick Reynolds, M.D., Ph.D., director for the School of Medicine Cancer Center at the Texas Tech University Health Sciences Center.

23 Mar 2022

Reducing mucin secretion provides a way to control chemoresistance of colorectal cancers

Drugs which are commonly-used as the first line of treatment for colorectal cancer cause the tumor cells to oversecrete proteins known as mucins, according to a new study published today in the journal eLife.

9 Feb 2022

Researchers identify new drug that makes pancreatic cancer cells more vulnerable to chemotherapy

Researchers at Washington University School of Medicine in St. Louis have identified a drug compound that makes pancreatic cancer cells more vulnerable to chemotherapy.

1 Dec 2021

Researchers compare transcriptomic and cytokine responses of colorectal cancer cells

Oncotarget published "Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells" which reported that there was an increase in IL-8 by oxaliplatin and increase in ferritin by cisplatin which may contribute to cancer cell survival.

29 Sep 2021

Topoisomerase 1 inhibition prevents SARS-CoV-2-induced inflammation and death in animal models

A new study indicates that the topoisomerase 1 (Top1) is intimately related to the lethal inflammation associated with SARS-CoV-2 infection in a large proportion of cases.

7 Dec 2020

UH professor is developing a Chinese herbal medicine formula to improve cancer therapy

University of Houston professor of pharmaceutics Ming Hu is developing and testing an ancient Chinese herbal medicine formula, first described in 280 A.D., to improve cancer therapy.

4 Nov 2020

Biomarkers that are predictive of clinical benefit in Trop-2-expressing triple-negative breast cancer

Oncotarget recently published "Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer" which reported that the authors investigated whether Trop-2-expression and homologous recombination repair of SN-38-mediated double-strand DNA breaks play a role in the sensitivity of triple-negative breast cancer to SG.

3 Nov 2020

PI3K/mTOR and topoisomerase inhibitors suggested as candidates to reduce expression of ACE2

A recent study published in the preprint server medRxiv in September 2020 shows that the already approved drug families called P13K/mTOR and topoisomerase inhibitors may be useful in reducing individual susceptibility to the virus.

7 Sep 2020

First comparative data of encorafenib and paradox breaker inhibitors in BRAF mutant CRC

Oncotarget Volume 11, Issue 34 features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et al which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib.

26 Aug 2020

Potential inhibitors of SARS-CoV-2 identified

Now, a new study published on the preprint server bioRxiv in August 2020 reports the discovery of two inhibitors of the helicase enzyme, which is essential for viral replication and the most highly conserved non-structural coronavirus (CoV) protein.

16 Aug 2020

COMBAT study shows how pancreatic cancer patients can benefit from immunotherapy

Working with an international team of researchers, HonorHealth Research Institute and the Translational Genomics Research Institute, an affiliate of City of Hope, were instrumental in one of the first clinical trials showing how pancreatic cancer patients can benefit from immunotherapy, according to a four-year study published in a premier scientific journal, Nature Medicine.

11 Aug 2020

Small molecule drugs binding Mac1 domain of SARS-CoV-2

Now, an intriguing new study out of the University of Wisconsin-Milwaukee reveals that numerous small molecule drugs like the proton pump inhibitors omeprazole and rabeprazole bind the important Mac1 domain on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus.

8 Jul 2020

SWOG scientists to deliver online presentations at ASCO20 Virtual Scientific Program

Researchers from SWOG, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, will make 31 presentations as part of the ASCO20 Virtual Scientific Program, the online annual meeting of the American Society of Clinical Oncology (ASCO), which runs May 29-31.

19 May 2020